Case Study | April 9, 2025
Improving AMR Research with Smarter Drug Discovery Data Management: A BioVersys Case Study
TL;DR
As BioVersys expanded its antimicrobial research programs, it needed a more structured way to manage chemical, biological, and selected clinical data across internal teams and external collaborators. Working across international partnerships and resistant pathogens such as MRSA, tuberculosis, and Acinetobacter baumannii required faster access to current and historical results, clearer side-by-side analysis, and more consistent reporting. Using CDD Vault as its shared data environment, BioVersys created a more scalable foundation for collaborative AMR drug discovery.
Introduction to BioVersys Drug Discovery Data Management
This case study explores how BioVersys transformed its data processes using CDD Vault to streamline collaboration, support regulatory demands, and enable real-time insight sharing across its AMR pipeline.
As the global crisis of antimicrobial resistance (AMR) intensifies, innovative biotech companies are stepping in to fill the gap left by large pharmaceutical firms. Swiss-based BioVersys is at the forefront of this movement, building solutions to combat drug-resistant infections with targeted, next-generation antimicrobials. But with high-stakes projects spanning multiple countries and partners, effective drug discovery data management has become a critical requirement—not just for speed and accuracy, but for survival.
Findings: AMR & Drug Discovery Data Management
The path to discovering new antibiotics is fraught with financial, logistical, and technical hurdles. Part of the challenge lies in managing cross-functional teams working across multiple countries and disciplines. In its early days, BioVersys operated on a small scale where data could be tracked manually. But as its pipeline matured and expanded, the company recognized that traditional tools were no longer sufficient. The lack of a scalable, structured system for drug discovery data management began to hinder progress.
At the same time, BioVersys’ work in AMR surveillance and development of treatments targeting MRSA, TB, and Acinetobacter baumannii required rigorous, real-time tracking of antibiotic resistance data. To stay ahead in the fight against resistant infections, they needed a system that could unify teams, ensure data integrity, and support the fast-paced evolution of AMR data from discovery through clinical trials.
Find out how CDD Vault can support Drug Discovery Data Management
Find out how CDD Vault can support Drug Discovery Data Management
As BioVersys grew, its manual methods of tracking data began to break down under the weight of multiple global projects. Implementing CDD Vault gave the company a flexible, secure, and scalable foundation for effective drug discovery data management.
- Early systems relied on individuals manually updating experimental results and databases.
- As teams expanded, keeping data current became time-consuming and error-prone.
- BioVersys implemented CDD Vault to centralize chemical, biological, and clinical information in a structured format.
- The new system allowed multiple users to input and retrieve data in real time, streamlining internal workflows and collaboration.
“We rely on our data management processes and infrastructure to ensure that we capture all of our data, enhance internal communication, and empower teams to generate insights.”
- Andrej Trauner, Project Manager
Managing MRSA Projects Across Borders
One of BioVersys' most urgent programs targets MRSA, a leading cause of death related to antimicrobial resistance. The ability to seamlessly share compound, assay, and toxicity data across four countries became possible with the help of CDD Vault.
- The MRSA initiative involved collaboration between sites in Switzerland and France, with supporting partners across Europe.
- CDD Vault enabled consistent data formatting, allowing side-by-side comparisons of in vitro potency, pharmacokinetics, and toxicity data.
- Having structured access to real-time and historical data ensured more confident decision-making in lead optimization stages.
- The platform enabled effective sharing of antibiotic resistance data relevant to this and other bacterial targets.
Supporting AMR Surveillance and Data Transparency
For companies developing antibiotics, contributing to global AMR surveillance efforts requires both speed and traceability. With CDD Vault, BioVersys ensured that its AMR data could be securely accessed, version-controlled, and transparently reported.
- CDD Vault supports internal tracking of compound resistance profiles, including historical AMR data trends.
- Visualization tools, including dose-response curves and searchable substructure features, helped teams identify blind spots in datasets.
- The team could quickly share and interpret data during cross-partner discussions and consortia meetings.
- The platform also made it easier to comply with data-sharing expectations from public and non-profit collaborators.
“We aim to generate databases that span disciplines so we can cross-reference data, find correlations, and identify issues before they become problems.”
Unifying Research for Greater Antibiotic Impact
BioVersys is part of several international collaborations, and its future depends on transparency and alignment with global stakeholders. With a system designed for collaborative workflows, CDD Vault helped unify drug discovery data management and reporting across projects.
- Participating in initiatives like CARB-X and the Innovative Medicines Initiative requires strict data governance.
- CDD Vault provided the flexibility to adapt data models for different funding partners and research consortia.
- Even non-specialists could navigate datasets thanks to intuitive visualization and curve-fitting tools.
- This level of usability promotes inclusivity across public-private partnerships fighting antimicrobial resistance.
“It would be almost impossible to develop a new product without close interaction between the private and public sectors. In that respect, the future of antimicrobial development is collaborative.”
Conclusion
As antimicrobial resistance threatens global health, companies like BioVersys are proving that innovation doesn’t end with drug development—it extends to how research is managed and shared. With CDD Vault, BioVersys has built a scalable foundation for efficient, collaborative, and transparent drug discovery data management that supports everything from early screening to clinical readiness.
The ability to track, cross-reference, and securely share AMR data in real time has helped BioVersys advance its mission: creating novel therapeutics for the world’s most dangerous resistant infections. From MRSA to tuberculosis, BioVersys is accelerating progress in one of the most critical areas of modern medicine.
Recommendations
To effectively combat the rising tide of antimicrobial resistance, research organizations—especially small to mid-sized biotechs—should prioritize implementing flexible and centralized drug discovery data management systems.
Platforms like CDD Vault not only improve operational efficiency but also enhance collaboration across teams and consortia focused on AMR surveillance and the integration of high-value antibiotic resistance data.
In a field where timely insight and global cooperation are essential, having the right infrastructure in place can mean the difference between reactive research and proactive impact.
References / Bibliography
- World Health Organization. (2023). Antimicrobial resistance. https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
- BioVersys. (2024). Pipeline and Projects. https://www.bioversys.com
- Collaborative Drug Discovery. (2024). CDD Vault Overview. https://www.collaborativedrug.com
- CARB-X. (2024). Combating Antibiotic-Resistant Bacteria. https://carb-x.org
- Innovative Medicines Initiative. (2024). Public-private partnerships for better health. https://www.imi.europa.eu
Additional Resources
View All Posts
News
1 min
September 3, 2025
Data as the New Gold: Innovation with Capital-Efficiency
Read More
CDD Blog
8 min
October 22, 2018
Why Is Publicly Available Data Important And How Is It Being Used?
Read More
Collaborative Drug Discovery
4 min
February 26, 2026
Secure CRO Collaboration Without Losing Scientific Context
Read More
Ready to get started?
Our friendly team will show you how easy it is to enhance your data workflow with CDD Vault.
Why did BioVersys need a new data management solution?
As BioVersys grew, its existing data processes became too manual and person-dependent. The company needed a centralized system to manage and share chemical and biological data across projects, sites, and research partners.
How does CDD Vault support antibiotic discovery at BioVersys?
CDD Vault gives BioVersys a shared system for compound structures, in vitro potency data, dose-response curves, ADME, and toxicity data. This helps teams compare results side by side, cross-reference data across disciplines, and share updates in real time.
What CDD Vault capabilities are especially valuable to BioVersys?
BioVersys highlights CDD Vault’s side-by-side data analysis, curve-fitting, substructure searching, intuitive interface, and built-in tools for first-pass analysis. These features make it easier for both specialists and non-specialists to explore data and draw conclusions.